Literature DB >> 15579015

Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.

Philippe de Médina1, Gilles Favre, Marc Poirot.   

Abstract

Tamoxifen is a well-known antiestrogen used for the hormonotherapy of estrogen receptor positive breast cancer. In addition to its high affinity binding to the estrogen receptor (ER), tamoxifen binds with comparable affinity to the microsomal antiestrogen binding site (AEBS), and inhibits with a micromolar efficiency, protein kinase C (PKC), calmodulin (CaM)-dependent enzymes and Acyl CoenzymeA: Cholesterol Acyl Transferase (ACAT). Each of these tamoxifen targets might explain the genomic as well as non-genomic effects of tamoxifen. In this review, we will report current knowledge about the structural features of tamoxifen involved in this multiple targeting. These data provide a useful guide for the conception of selective ligands of ERs, AEBS, PKC, CaM or ACAT based on the chemical structure of tamoxifen.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579015     DOI: 10.2174/1568011043352696

Source DB:  PubMed          Journal:  Curr Med Chem Anticancer Agents        ISSN: 1568-0118


  24 in total

Review 1.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

2.  Synthesis and biological evaluation of novel tamoxifen-1,2,4-triazole conjugates.

Authors:  M S R Murty; Mohana Rao Katiki; Jagadeesh Babu Nanubolu; Srujana Garimella; Sowjanya Polepalli; Nishant Jain; Sudheer Kumar Buddana; R S Prakasham
Journal:  Mol Divers       Date:  2016-06-08       Impact factor: 2.943

3.  Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.

Authors:  Colleen Carpenter; Roderick J Sorenson; Yafei Jin; Szymon Klossowski; Tomasz Cierpicki; Margaret Gnegy; Hollis D Showalter
Journal:  Bioorg Med Chem       Date:  2016-09-04       Impact factor: 3.641

Review 4.  Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?

Authors:  Sarah Mikelman; Natalie Mardirossian; Margaret E Gnegy
Journal:  J Chem Neuroanat       Date:  2016-08-30       Impact factor: 3.052

5.  Synthesis and characterization of fluorescent 4-hydroxytamoxifen conjugates with unique antiestrogenic properties.

Authors:  Emily L Rickert; Sean Oriana; Cori Hartman-Frey; Xinghua Long; Timothy T Webb; Kenneth P Nephew; Ross V Weatherman
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

6.  The cancer drug tamoxifen: a potential therapeutic treatment for spinal cord injury.

Authors:  Jutatip Guptarak; John E Wiktorowicz; Rovshan G Sadygov; Dragoslava Zivadinovic; Adriana A Paulucci-Holthauzen; Leoncio Vergara; Olivera Nesic
Journal:  J Neurotrauma       Date:  2013-12-11       Impact factor: 5.269

7.  Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.

Authors:  Colleen Carpenter; Alexander G Zestos; Rachel Altshuler; Roderick J Sorenson; Bipasha Guptaroy; Hollis D Showalter; Robert T Kennedy; Emily Jutkiewicz; Margaret E Gnegy
Journal:  Neuropsychopharmacology       Date:  2017-05-11       Impact factor: 7.853

8.  Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands.

Authors:  Philippe de Medina; Michael R Paillasse; Gregory Segala; Marc Poirot; Sandrine Silvente-Poirot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

9.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach.

Authors:  Xiaofeng Liu; Sisheng Ouyang; Biao Yu; Yabo Liu; Kai Huang; Jiayu Gong; Siyuan Zheng; Zhihua Li; Honglin Li; Hualiang Jiang
Journal:  Nucleic Acids Res       Date:  2010-04-29       Impact factor: 16.971

10.  Protein kinases C isozymes are differentially expressed in human breast carcinomas.

Authors:  Shadan Ali; Sana Al-Sukhun; Bassel F El-Rayes; Fazlul H Sarkar; Lance K Heilbrun; Philip A Philip
Journal:  Life Sci       Date:  2009-03-24       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.